Melanoma development and progression is thought to be the result of a multi-step accumulation of genetic damage, with loss of heterozygosity in chromosome 9p (MTS1) frequently described. In addition, chromosome 10q allelic loss has been reported, implicating the tumor suppressor gene PTEN/MMAC1 on 10q23.3. The MXI1 gene at 10q24 -25 is another candidate tumor suppressor that has only rarely been studied in melanomas, with conflicting results. We used microdissectionbased genotyping to investigate 29 melanomas from 20 patients for loss of heterozygosity in intragenic and flanking microsatellite markers for this latter gene. Concurrently, the MTS1 gene was similarly studied using two flanking microsatellites. Fiftyfour percent (15 of 28) of the informative cases showed loss of heterozygosity for one or both MXI1 markers, as compared with 67% (16 of 24) of the informative cases for MTS1. MXI1 allelic loss was seen more frequently in recurrent/metastatic tumors (59%), as compared with in primary (33%) lesions. Eighty percent of the primary tumors showed loss of heterozygosity for MTS1, as well as 63% of recurrent/metastatic ones. We studied more than one tumor in eight patients, with those from three patients showing discordant genetic patterns. One patient showed a metastatic tumor with allelic loss for MXI1 that was not identified in the primary melanoma or a local recurrence. The other two patients showed clonal heterogeneity in MXI1 at synchronous and metachronous metastatic foci. These findings support MXI1 as a putative tumor suppressor gene involved in conventional melanoma progression. Genetic heterogeneity seen in different metastases from the same primary suggests a nonlinear pattern of chromosomal damage, with the development of multiple clones within the primary tumor, each acquiring its own metastatic potential.
Melanoma is a significant health concern among the Caucasian population and is typically characterized by aggressive biologic behavior, with eventual metastasis and death. Tumorigenesis is thought to be associated with a multistep, temporal accumulation of genetic alterations (1) , and in an attempt to understand its biology, the molecular pathogenesis of these lesions is being continuously investigated. Of the chromosomal abnormalities encountered, allelic imbalances of chromosome 9p21, which harbors the MTS1 gene are those frequently described in both sporadic and familial melanomas (2) (3) (4) (5) (6) (7) . Mutations involving the long arm of chromosome 10 have also been reported in sporadic primary and metastatic melanomas at frequencies ranging from 31 to 58% (4, 5, 8 -11) and have been associated with a poor prognosis (4, 8) .
The Max interacting protein (MXI1) is a tumor suppressor gene mapped to chromosome 10q24 -25. Deletion of genetic material from this site is commonly seen in neural crest-associated tumors such as glioblastomas (12) . Rao et al. (11) demonstrated MXI1 loss of heterozygosity (LOH) in 46% of the primary and metastatic desmoplastic melanomas that they studied, postulating that the embryologic neuroectodermal origin of desmoplastic melanomas may account for this similarity with glioblastomas. Extrapolating on this further, it would not be surprising if conventional melanomas should show similar allelic imbalances in the MXI1 gene. Herbst et al. (13) , however, in their study of 65 sporadic primary and metastatic melanomas, found only 7 to 13% LOH for this gene. To our knowledge, these are the only two published studies in the English literature on MXI1 in melanomas.
We thus sought to further investigate the role of the MXI1 gene in the pathogenesis and progression of conventional melanomas by using a microdissection-based genotyping technique to look for LOH using two microsatellite markers for this gene. We compared these findings to those seen in the MTS1 gene on 9p21.
MATERIALS AND METHODS
Seven primary, 2 recurrent, and 20 metastatic melanomas were identified from the files of the Presbyterian and Montefiore University Hospitals of the University of Pittsburgh Medical Center. Paraffin-embedded blocks were obtained for each of the 29 cases, and clinical information was extracted from the Medical Archives Retrieval System. Serial 4-m-thick unstained histologic sections were microdissected under stereoscopic observation, as described elsewhere (14) . For each tumor sample, representative uninvolved dermis of approximately equal size was also obtained as a normal control. The microdissected samples were treated with 50 L of proteinase K (10 ng/mL) for 2 hours and boiled for 5 minutes to remove enzyme activity.
Each sample was PCR amplified in individual reactions using oligonucleotide primers targeted at microsatellite repeats of the MXI1 and MTS1 genes. For MXI1, we used an intragenic microsatellite (3NT) in the 3' nontranslating region of the gene (12) , and the flanking repeat unit D10s1173 (GenBank accession no. L30341). MTS1 was studied using two flanking microsatellites D9s251 and D9s254 (GenBank accession nos. L18726 and L18050, respectively). The primers for MXI1.3NT were 5'-GGTTACTCCAGTGCC-AGTGT-3' (sense) and 5'-TTAAATACAGGTCCTCTG-ACCC-3' (antisense); for D10s1173, they were 5'-CATGCCAAGACTGAAACTCC-3' (sense) and 5'-AAACCCCAATGCCATAATGG-3' (antisense); for D9s251, they were 5'-CCTGTGTTGAAATTTTGACTG-3' (sense) and 5'-ATTTCAGACTTCCTTGTGTTC-3' (antisense); and for D9s254, they were 5'-TCCTGGGTAATAA-CTGCCG-3' (sense) and 5'-CACTCACACACACGC-TCAG-3' (antisense). After initial denaturation at 95°f or 10 minutes, 35 cycles of PCR were carried out with denaturation at 94°C for 1 minute, annealing at 58°C for 1 minute, and polymerization at 74°C for 1 minute, with a final 10-minute extension at 74°C. The amplified products were labeled with [P 33 ]-deoxyadenine triphosphate and electrophoresed in 6% polyacrylamide. Loss of heterozygosity was determined by comparing the intensity of the polymorphic bands from normal and tumor tissue. To control for allelic dropout caused by insufficient sample size, the bands from normal tissue were required to be of similar intensity to justify analysis of the tumor samples.
RESULTS
Twenty patients were identified with 7 primary, 2 recurrent and 20 metastatic melanomas (Table 1) . Overall, both genes showed similar degrees of allelic loss, 54% for MXI1 and 67% for MTS1. For the MXI1 gene, comparing primary and recurrent/metastatic lesions, 6 and 22, respectively were informative for one or both markers. LOH was seen in 2 (33%) and 13 (59%) of these (Fig. 1) . Similarly analyzing MTS1, 5 and 19 of primary and recurrent/ metastatic tumors were informative, with 4 (80%) and 12 (63%) showing LOH, respectively.
More than one tumor was sampled in eight patients. Of these, the pattern of LOH in both genes was identical in five. One of the discordant cases (Patient 1) was that of a primary melanoma of the left leg that was negative for LOH in MXI1 and recurred 6 months later with a similar result. The metastasis from 1 year later, however, showed acquisition of LOH in both loci of the MXI1 gene (Fig.  1) . MTS1 was not informative. Patient 10 had two distinct metastases sampled within 1 week of each other. The adrenal tumor showed LOH in all four gene loci studied, whereas the lung was positive in only one locus for each gene (MXI1.3NT and D9s251) and was negative in the other two. The primary tumor, a trunk melanoma from 19 years prior, was not available for analysis. The results from Patient 11 were of particular interest, with the two tumors studied representing neck lymph node and parotid gland metastases that were removed 6 and 8 years, respectively, after a right cheek primary. Although on initial inspection the pattern of gene loss appeared to be the same for both lesions, examination of the allelic bands lost for the MXI1.3NT microsatellite revealed that different ones were deleted in the separate metastases and thus represented genetically distinct clones (Fig. 1) .
DISCUSSION
Genetic alterations involving the long arm of chromosome 10 occur fairly commonly in primary and metastatic melanomas, with frequencies ranging from 31 to 58% (4, 5, 8 -11) . The gene most often implicated is PTEN/MMAC1 (9, 10), a tumor suppressor gene located on 10q23.3. Germline mutations of this gene have been associated with Cowden disease (multiple hamartoma syndrome), a rare autosomal-dominant familial cancer syndrome (15) . The MXI1 gene is also located on the long arm of chromosome 10 and has been mapped to chromosome 10q24 -25. This latter gene acts as a tumor suppressor by negatively regulating the myc oncoprotein. Allelic imbalances have been demonstrated in glioblastomas (12) ; however, to our knowledge, there have been only two prior studies in the English literature to determine its possible involvement in melanoma tumorigenesis. Herbst et al. (13) concluded that the low frequency of LOH (7 to 13%) at intragenic markers for MXI1 in conventional melanomas most likely represented random genetic rather than pathogenic events. Conversely, Rao et al. (11) found MXI1 LOH to be relatively frequent in desmoplastic melanomas, seen in 5 of 11 informative cases.
Our study, unlike that of Herbst et al. (13) , showed frequent LOH at intragenic and flanking loci of the MXI1 gene, with aberrations seen in 54% (15 of 28) of the informative cases of primary, recurrent, and metastatic melanomas. This is similar to the 45% LOH that was seen in the desmoplastic melanomas studied by Rao et al. (11) , although all of our cases were of the conventional type. When the primary melanomas were considered separately, only two of six informative cases (33%) demonstrated LOH. Conversely, 13 of 22 (59%) informative metastatic/recurrent lesions showed genetic loss. Although the number of primary lesions studied is small, this seems to suggest that genetic imbalance involving the MXI1 gene is a late event in tumorigenesis, associated with metastatic potential and spread. Further anecdotal support for this hypothesis is provided by Case 1, in which no LOH was detected in the primary or recurrent melanoma but there was acquisition of LOH in the groin metastasis at both the intragenic and flanking loci of the MXI1 gene (Fig. 1) .
The findings seen in Patients 10 and 11 are remarkable for their demonstration of genetic heter- 
F, female; M, male; P, primary; R, recurrent; Me, metastatic; LN, lymph node; NOS, not otherwise specified; ND, not done; N/A, not applicable; Ϫ, no loss of heterozygosity identified; ϩ, loss of heterozygosity identified; NI, sample not informative.
a Patient treated with immune therapy prior to excision of primary melanoma, and the specimen was partially submitted for cell culture prior to pathologic evaluation. Accurate pathologic staging thus could not be performed.
b Tumor involved the deep excision margin and no subcutaneous tissue was seen. The Breslow depth, Clark's level and TNM stage may thus be greater than reported. 
